Here are five things to know:
1. Ivan Grunberger, MD, chief of urology at New York Methodist Hospital and professor of clinical urology at Weill Cornell Medical College, performed the procedure. Judd Boczko, MD, assistant clinical professor of urology at New York Medical College practicing with Westmed Medical Group, assisted in the procedure.
2. The Ablatherm Robotic HIFU is FDA-cleared and designed to treat localized prostate cancer. The minimally invasive procedure is recommended for patients with localized prostate cancer stages T1-T2 who aren’t candidates for surgery or failed radiotherapy patients who prefer an alterative treatment option.
3. The technology is approved for commercial distribution in Europe as well as other countries. The company plans to implement the technology in major metropolitan areas in the United States.
4. American HIFU owns the Ablatherm Robotic HIFU and is mobilized to provide HIFU access to select urologists throughout the United States.
5. Gramercy Surgery Center opened in 2006 and includes ASCs in Manhattan and Queens. David Albert, MD, is director at the center and Jeffrey Flynn is COO. The center includes orthopedics, breast cancer surgery, bariatric surgery, general surgery, lithotripsy and gynecology, among other specialties.
More articles on surgery center:
NueHealth acquires Blue Chip Surgical Partners: 5 things to know
Outpatient surgery deemed safe, effective for total hip replacements—5 things to know
7 things for ASC leaders to know
